Navigation Links
A Recent Study by ITG's Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- A study published this week by ITG's Majestic Market Research revealed that Novartis' recently approved drug, Gilenya, continues to steal share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September 2010 as the first FDA-approved oral disease-modifying MS drug.  Despite negative sentiment around Gilenya's lengthy initiation process, neurologists are embracing the new drug at an impressive rate.  Real time data from ITG's proprietary physician panel indicate that Gilenya was the disease-modifying treatment of choice for 20% of new written MS prescriptions in April.  Furthermore, surveyed neurologists indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.

The study takes an in-depth look at how Gilenya's multi-step initiation process is impacting neurologists' use of the drug.  According to neurologists, new treatment starts for Gilenya typically take between three to six weeks and involve the scheduling and organization of prescreening tests and ongoing monitoring for adverse events.  

Physicians reported that Novartis plays an important role in facilitating these steps. In fact, 63% of Gilenya prescribers indicated that they receive support from Novartis during this process, and 25% of them classified this assistance as superior to what competing companies offer for their products.  

By comparison, neurologists appear unable to get over similar concerns about Acorda Therapeutics' Ampyra, which was launched in March 2010 as the first FDA approved drug to improve walking in MS patients. Like Gilenya, Ampyra is associated with an onerous initi
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
11. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2, 2014  InfinityQS International, Inc., the global ... announces key client speakers for Infusion Chicago, its ... The event will be held Oct. 9-10, 2014, ... include projects from Coloplast, The Kellogg Company, Biomet, ... King. The two-day event will also include best ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. announced ... new practice solely focused on the specific needs of ... While Softworld has already been highly successful in the ... additional capabilities to support the quality, regulatory, and validation ... now a combination of the current Biometric team and ...
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
Breaking Medicine Technology:InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5
... Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ... development, assembly, marketing and sale of medical devices and ... will participate in the MEDICA 2010 International Trade Fair, ... Fairgrounds in Dusseldorf, Germany. More than ...
... 2010 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced that BioSpecifics, President, Tom Wegman, will ... Healthcare Conference on Wednesday, November 17, 2010, at 2:45 ... New York. A live webcast of the ...
Cached Medicine Technology:Dehaier Medical to Participate in MEDICA International Trade Fair 2Dehaier Medical to Participate in MEDICA International Trade Fair 3
(Date:10/2/2014)... Dennis Thompson HealthDay ... A newborn,s risk of developing celiac disease isn,t reduced by ... in wheat called gluten to an infant,s diet help prevent ... pair of new studies in the Oct. 2 New ... to rest hopes that a child could avoid celiac disease ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... - Scientists at the Toronto Western Research Institute (TWRI), ... the brain against the damaging effects of a stroke ... development for a few years. At this point, it ... drugs created to reduce the brain,s vulnerability to stroke ...
... sudden urge to urinate, affects the quality of life of ... respond to or can tolerate oral medications and may benefit ... of Rhode Island is conducting a study to compare the ... urge incontinence after trying other treatments. Patients are currently ...
... there,s hope. In the March 2012 print issue of ... the University of Florida report that a family of ... role in the regulation of skeletal muscle mass. Specifically, ... transcription factors prevents muscle wasting associated with cancer and ...
... , This release is available in French ... University of Montreal and CHUM Hospital,s International Health, will be ... be working on the funding of the fight against Noma. ... of children mostly in Sub-Saharan Africa. Despite the existence of ...
... , TUESDAY, Feb. 28 (HealthDay News) -- Poor people ... more money are, a new study shows. This finding ... otherwise due to an "unconscious bias" they have against low-income ... Monterey Orthopaedic and Sports Medicine Institute in California, and colleagues. ...
... -- Researchers who used family trees dating back to ... inherited heart rhythm disorders say their findings can help ... with these disorders. Sudden cardiac death can occur ... Genetic testing can identify people with an inherited heart ...
Cached Medicine News:Health News:Canadian scientist develops world's most advanced drug to protect the brain after a stroke 2Health News:Women & Infants studying therapies to relieve urinary urge incontinence 2Health News:No workout? No worries: Scientists prevent muscle loss in mice, despite disease and inactivity 2Health News:Montrealer heads to Congo to fight childhood disfigurement 2Health News:Poor Patients Less Likely to Sue Doctors, Analysis Shows 2Health News:Family Tree May Aid Treatment of Inherited Heart Disorders 2
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
... active hormone synthesized within the follicular cells ... synthesized via a series of steps involving: ... (ii) iodination of tyrosine residues in the ... and 3,5-diiodotyrosine (MIT and DIT), and (iii) ...
... factor binding protein-3 (IGFBP-3) is the main binding ... as a component of the ~150 kDa ternary ... of IGF-I or IGF-II and ALS, allowing IGFBP-3, ... the IGFs. The molar concentration of IGFBP-3 in ...
... (GH) is a monomeric protein produced and ... gland. GH is released from the pituitary ... under the regulatory control of hypothalamic somatostatin ... timing and frequency of GH release appears ...
Medicine Products: